cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Rachmat Hidayat
Contact Email
dr.rachmat.hidayat@gmail.com
Phone
+6281949581088
Journal Mail Official
hanifmedisiana@gmail.com
Editorial Address
Jl. Sirna Raga no 99, 8 Ilir, Ilir Timur 3, Palembang
Location
Kota palembang,
Sumatera selatan
INDONESIA
Archives of The Medicine and Case Reports
Published by HM Publisher
ISSN : -     EISSN : 27472051     DOI : https://doi.org/10.37275/amcr
Core Subject : Health,
Health Professions Medicine & Pharmacology Nursing Public Health
Archives of The Medicine and Case Reports (AMCR) is a broad scope journal aims to publish the most exciting Case studies/reports in Clinical and Medical Sciences. AMCR aims to provide an excellent platform for Clinical Practitioners, medical/ health practitioners, students, professionals, researchers in medicine. AMCR accept any original case report that expands the field of general medical knowledge, and original research relating to case reports including report of the symptoms, diagnosis, treatment, and follow-up of an individual patient. The journal covers all medical specialties including : • Oncology • Paediatrics • Respiratory disorders • Allergy • Radiology • Nephrology • Neurology • Haematology • Immunology • Radiology • Nuclear medicine • Medical imaging • Audiovestibular medicine • Cardiology and cardiovascular systems • Critical care medicine • Dermatology • Emergency medicine • Endocrinology and metabolism • Gastroenterology and hepatology • Geriatrics and gerontology • Infectious diseases and treatment • Medical disorders in pregnancy • Medical ophthalmology • Sports Medicine • Substance abuse • Palliative medicine • Psychiatry • Rheumatology • Sexual and reproductive health
Arjuna Subject : Kedokteran - Kedokteran (Lain-Lain)
Articles 222 Documents
 19   20   21   22   23 
The Prognostic Superiority of Early ΔNLR Variations in Predicting In-Hospital Mortality among Emergency and Ward Patients with COVID-19: A Systematic Review and Meta-Analysis Ayu Sandra Manikasari; Ni Kadek Nadia Ayu Agustini
Archives of The Medicine and Case Reports Vol. 7 No. 2 (2026): Archives of The Medicine and Case Reports
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/amcr.v7i2.870

Abstract

The neutrophil-to-lymphocyte ratio is an established biomarker reflecting systemic inflammation and immune dysregulation. However, single baseline measurements upon hospital admission often fail to capture the highly dynamic immunological trajectory of patients infected with the severe acute respiratory syndrome coronavirus 2. This study aimed to evaluate the prognostic superiority of early variations in the neutrophil-to-lymphocyte ratio, defined as ΔNLR, compared to static baseline measurements for predicting in-hospital mortality among patients admitted to the emergency department and general medical wards. A systematic review and meta-analysis were strictly conducted according to PRISMA guidelines. Data were meticulously extracted from ten selected observational cohort studies. The primary outcome assessed was in-hospital mortality. Standardized mean differences and 95 percent confidence intervals were calculated utilizing a DerSimonian-Laird random-effects model to appropriately account for anticipated clinical heterogeneity. The comprehensive meta-analysis integrated data from 4582 patients across ten independent studies. Both the baseline neutrophil-to-lymphocyte ratio and the early ΔNLR were significantly elevated in non-survivors compared to survivors. However, the early variation in the ratio, measured precisely at 24 to 48 hours post-admission, demonstrated a significantly higher predictive value for in-hospital mortality. The pooled standardized mean difference for baseline measurements between non-survivors and survivors was 0.82 (95 percent confidence interval: 0.61 to 1.03, p less than 0.001). In stark contrast, the pooled standardized mean difference for the early ΔNLR was 1.34 (95 percent confidence interval: 1.05 to 1.63, p less than 0.001), indicating a substantially stronger effect size and superior prognostic discrimination. In conclusion, early dynamic variations in the neutrophil-to-lymphocyte ratio offer superior prognostic value compared to static baseline measurements for predicting fatal outcomes in COVID-19 patients. Integrating kinetic monitoring into emergency and ward triage protocols can significantly optimize early risk stratification.
Re-evaluating Immediate, Adjuvant, and Salvage Intravesical Chemotherapy in Non-Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Gemcitabine Non-Inferiority to Mitomycin C Reza Abdia Jauhari
Archives of The Medicine and Case Reports Vol. 7 No. 2 (2026): Archives of The Medicine and Case Reports
Publisher : HM Publisher

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.37275/amcr.v7i2.863

Abstract

Non-muscle-invasive bladder cancer demonstrates a uniquely high propensity for recurrence following initial transurethral resection of bladder tumor. A single, immediate post-operative instillation of chemotherapy became the established standard to mitigate this risk. Mitomycin C historically functioned as the agent of choice; however, frequent drug shortages and significant local toxicity profiles necessitated the rigorous evaluation of viable alternatives. Gemcitabine, a pyrimidine nucleoside analogue, emerged as a promising candidate. This study aimed to evaluate the comparative efficacy and safety of gemcitabine versus mitomycin C across immediate post-operative, adjuvant, and salvage clinical settings. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines. The analysis utilized data from seven key comparative trials evaluating gemcitabine versus mitomycin C. A highly specific search strategy isolated direct head-to-head comparative studies. Data extraction focused exclusively on recurrence rates, time to recurrence, and adverse events. Pooled Odds Ratios and Standardized Mean Differences were calculated using a DerSimonian-Laird random-effects model. Sensitivity analyses isolating randomized controlled trials and excluding upper tract urothelial carcinoma data were explicitly performed. Five primary studies provided head-to-head comparative data for recurrence, comprising 405 patients. Two additional studies evaluated sequential salvage therapy. Adjuvant gemcitabine regimens demonstrated a significant reduction in recurrence compared to mitomycin C (Odds Ratio 0.38, 95 percent Confidence Interval 0.19 to 0.75). In strictly immediate single-dose settings, mitomycin C demonstrated a trend toward superior recurrence prevention over gemcitabine (Odds Ratio 1.65). Toxicity analysis heavily favored gemcitabine, showing a significantly lower incidence of chemical cystitis (Odds Ratio 0.22). Sequential salvage therapy yielded a 30 percent to 37 percent long-term recurrence-free survival. In conclusion, gemcitabine demonstrated non-inferiority to Mitomycin C regarding overall oncological safety and exhibited a markedly superior tolerability profile. Mitomycin C retained a marginal advantage in the strict immediate post-operative window due to its potent cell-cycle-independent action. However, Gemcitabine's efficacy in adjuvant settings and favorable side-effect profile established it as a highly rational alternative.

Page 23 of 23 | Total Record : 222

 19   20   21   22   23 

Filter by Year

2020 2026


Reset
Filter By Issues
All Issue Vol. 7 No. 2 (2026): Archives of The Medicine and Case Reports Vol. 7 No. 1 (2026): Archives of The Medicine and Case Reports Vol. 6 No. 4 (2025): Archives of The Medicine and Case Reports Vol. 6 No. 3 (2025): Archives of The Medicine and Case Reports Vol. 6 No. 2 (2025): Archives of The Medicine and Case Reports Vol. 6 No. 1 (2025): Archives of The Medicine and Case Reports Vol. 5 No. 4 (2024): Archives of The Medicine and Case Reports Vol. 5 No. 3 (2024): Archives of The Medicine and Case Reports Vol. 5 No. 2 (2024): Archives of The Medicine and Case Reports Vol. 5 No. 1 (2024): Archives of The Medicine and Case Reports Vol. 4 No. 6 (2023): Archives of The Medicine and Case Reports Vol. 4 No. 5 (2023): Archives of The Medicine and Case Reports Vol. 4 No. 4 (2023): Archives of The Medicine and Case Reports Vol. 4 No. 3 (2023): Archives of The Medicine and Case Reports Vol. 4 No. 2 (2023): Archives of The Medicine and Case Reports Vol. 4 No. 1 (2023): Archives of The Medicine and Case Reports Vol. 3 No. 4 (2022): Archives of The Medicine and Case Reports Vol. 3 No. 3 (2022): Archives of The Medicine and Case Reports Vol. 3 No. 2 (2022): Archives of The Medicine and Case Reports Vol. 3 No. 1 (2022): Archives of The Medicine and Case Reports Vol. 2 No. 4 (2021): Archives of The Medicine and Case Reports Vol. 2 No. 3 (2021): Archives of The Medicine and Case Reports Vol. 2 No. 2 (2021): Archives of The Medicine and Case Reports Vol. 2 No. 1 (2021): Archives of The Medicine and Case Reports Vol. 1 No. 2 (2020): Archives of The Medicine and Case Reports Vol. 1 No. 1 (2020): Archives of The Medicine and Case Reports More Issue